Healthy 1st-qtr growth reported Novo Nordisk, which beats forecasts

1 May 2014

Danish diabetes care giant Novo Nordisk (NOV: N) increased operating profit in local currencies by 15% in the first quarter of 2014, helped by 7% sales growth in local currencies driven by Levemir (insulin detemir) and Victoza (liraglutide), the company reported this morning.

Sales increased by 7% in local currencies and by 2% in Danish kroner to 20.3 billion kroner ($3.76 billion). Earnings before interest and tax (EBIT) increased by 7% in Danish kroner to 8.30 billion kroner, beating the 7.87 billion kroner forecast by analysts polled by Reuters. Net profit increased 8% to 6.5 billion kroner. Diluted earnings per share increased by 10% to 2.43 kroner.

Cuts full-year guidance

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK